Apoptosis as a mechanism for liver disease progression.

PubWeight™: 1.21‹?› | Rank: Top 10%

🔗 View Article (PMC 3071245)

Published in Semin Liver Dis on October 19, 2010

Authors

Maria Eugenia Guicciardi1, Gregory J Gores

Author Affiliations

1: College of Medicine, Mayo Clinic, Rochester, MN, USA.

Articles citing this

Cell survival, DNA damage, and oncogenic transformation after a transient and reversible apoptotic response. Mol Biol Cell (2012) 1.25

Prevention of hepatocellular carcinoma: potential targets, experimental models, and clinical challenges. Curr Cancer Drug Targets (2012) 1.23

Role of ceramides in nonalcoholic fatty liver disease. Trends Endocrinol Metab (2012) 1.20

Genome-wide association study identifies variants associated with progression of liver fibrosis from HCV infection. Gastroenterology (2012) 1.09

c-FLIP maintains tissue homeostasis by preventing apoptosis and programmed necrosis. Sci Signal (2012) 1.01

Cellular and molecular mechanisms in the pathogenesis of liver fibrosis: An update. World J Gastroenterol (2014) 0.97

Pathogenesis and prevention of hepatitis C virus-induced hepatocellular carcinoma. J Hepatol (2014) 0.96

Pathophysiology of NASH: perspectives for a targeted treatment. Curr Pharm Des (2013) 0.95

Etiopathogenesis of nonalcoholic steatohepatitis: role of obesity, insulin resistance and mechanisms of hepatotoxicity. Int J Hepatol (2012) 0.95

Hepatocyte Nicotinamide Adenine Dinucleotide Phosphate Reduced Oxidase 4 Regulates Stress Signaling, Fibrosis, and Insulin Sensitivity During Development of Steatohepatitis in Mice. Gastroenterology (2015) 0.93

Molecular mechanisms underlying chemical liver injury. Expert Rev Mol Med (2012) 0.91

Crimean-Congo hemorrhagic fever virus-infected hepatocytes induce ER-stress and apoptosis crosstalk. PLoS One (2012) 0.91

Liver Injury and the Activation of the Hepatic Myofibroblasts. Curr Pathobiol Rep (2013) 0.89

ApoptoProteomics, an integrated database for analysis of proteomics data obtained from apoptotic cells. Mol Cell Proteomics (2011) 0.87

Naofen promotes TNF-α-mediated apoptosis of hepatocytes by activating caspase-3 in lipopolysaccharide-treated rats. World J Gastroenterol (2014) 0.84

Augmenter of liver regeneration. Fibrogenesis Tissue Repair (2012) 0.83

18α-Glycyrrhizin induces apoptosis and suppresses activation of rat hepatic stellate cells. Med Sci Monit (2012) 0.81

The role of death effector domain-containing proteins in acute oxidative cell injury in hepatocytes. Free Radic Biol Med (2012) 0.81

Extracellular matrix and liver disease. Antioxid Redox Signal (2014) 0.80

Establishment of a standardized liver fibrosis model with different pathological stages in rats. Gastroenterol Res Pract (2012) 0.80

Protection against Fas-induced fulminant hepatic failure in liver specific integrin linked kinase knockout mice. Comp Hepatol (2011) 0.80

Amelioration of carbon tetrachloride-induced cirrhosis and portal hypertension in rat using adenoviral gene transfer of Akt. World J Gastroenterol (2013) 0.80

Pathophysiological Significance of Hepatic Apoptosis. ISRN Hepatol (2012) 0.79

Natural killer cell-dependent anti-fibrotic pathway in liver injury via Toll-like receptor-9. PLoS One (2013) 0.78

Towards a three-dimensional microfluidic liver platform for predicting drug efficacy and toxicity in humans. Stem Cell Res Ther (2013) 0.78

Pertussis toxin, an inhibitor of G(αi) PCR, inhibits bile acid- and cytokine-induced apoptosis in primary rat hepatocytes. PLoS One (2012) 0.77

Liver Bid suppression for treatment of fibrosis associated with non-alcoholic steatohepatitis. J Hepatol (2015) 0.76

TRAIL dependent fratricidal killing of gp120 primed hepatocytes by HCV core expressing hepatocytes. PLoS One (2011) 0.76

Role of TLR4-Mediated PI3K/AKT/GSK-3β Signaling Pathway in Apoptosis of Rat Hepatocytes. Biomed Res Int (2015) 0.75

Ionone Derivatives from the Mycelium of Phellinus linteus and the Inhibitory Effect on Activated Rat Hepatic Stellate Cells. Int J Mol Sci (2016) 0.75

Mechanism of Hepatocyte Apoptosis. J Cell Death (2016) 0.75

Keratin 18, Apoptosis, and Liver Disease in Children. Curr Pediatr Rev (2011) 0.75

Toll-like receptors in secondary obstructive cholangiopathy. Gastroenterol Res Pract (2011) 0.75

Protective effect of propofol preconditioning on ischemia-reperfusion injury in human hepatocyte. J Thorac Dis (2017) 0.75

Elevation of Alanine Aminotransferase Activity Occurs after Activation of the Cell-Death Signaling Initiated by Pattern-Recognition Receptors ‎but before Activation of Cytolytic Effectors in NK or CD8+ T Cells in the Liver During Acute HCV Infection. PLoS One (2016) 0.75

Inhibitory effect of oxymatrine on hepatocyte apoptosis via TLR4/PI3K/Akt/GSK-3β signaling pathway. World J Gastroenterol (2017) 0.75

New Concepts on Pathogenesis and Diagnosis of Liver Fibrosis; A Review Article. Middle East J Dig Dis (2016) 0.75

Articles cited by this

Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics. Br J Cancer (1972) 35.74

Proapoptotic BAX and BAK: a requisite gateway to mitochondrial dysfunction and death. Science (2001) 23.42

The BCL-2 protein family: opposing activities that mediate cell death. Nat Rev Mol Cell Biol (2008) 20.89

Cleavage of BID by caspase 8 mediates the mitochondrial damage in the Fas pathway of apoptosis. Cell (1998) 16.08

Apoptosis by death factor. Cell (1997) 14.42

Bid, a Bcl2 interacting protein, mediates cytochrome c release from mitochondria in response to activation of cell surface death receptors. Cell (1998) 13.87

Mechanisms of hepatic fibrogenesis. Gastroenterology (2008) 11.98

Smac, a mitochondrial protein that promotes cytochrome c-dependent caspase activation by eliminating IAP inhibition. Cell (2000) 11.90

Hepatic stellate cells: protean, multifunctional, and enigmatic cells of the liver. Physiol Rev (2008) 10.28

Apoptosis: controlled demolition at the cellular level. Nat Rev Mol Cell Biol (2008) 8.30

The BCL-2 family reunion. Mol Cell (2010) 7.32

Lymphocyte apoptosis induced by CD95 (APO-1/Fas) ligand-expressing tumor cells--a mechanism of immune evasion? Nat Med (1996) 5.09

Acetaminophen-induced hepatotoxicity in mice is dependent on Tlr9 and the Nalp3 inflammasome. J Clin Invest (2009) 5.09

Nucleotides released by apoptotic cells act as a find-me signal to promote phagocytic clearance. Nature (2009) 4.98

Hepatocyte apoptosis and fas expression are prominent features of human nonalcoholic steatohepatitis. Gastroenterology (2003) 4.84

Cell death. N Engl J Med (2009) 4.75

In vivo assessment of liver cell apoptosis as a novel biomarker of disease severity in nonalcoholic fatty liver disease. Hepatology (2006) 4.60

A matter of life and death. Cancer Cell (2002) 4.07

Autoimmunity and the clearance of dead cells. Cell (2010) 3.90

Human caspases: activation, specificity, and regulation. J Biol Chem (2009) 3.67

Free fatty acids induce JNK-dependent hepatocyte lipoapoptosis. J Biol Chem (2006) 3.57

Toll-like receptor 9 promotes steatohepatitis by induction of interleukin-1beta in mice. Gastroenterology (2010) 3.52

Cellular and molecular mechanisms of liver injury. Gastroenterology (2008) 3.02

Apoptotic hepatocyte DNA inhibits hepatic stellate cell chemotaxis via toll-like receptor 9. Hepatology (2007) 2.82

Hepatocyte apoptosis, expression of death receptors, and activation of NF-kappaB in the liver of nonalcoholic and alcoholic steatohepatitis patients. Am J Gastroenterol (2004) 2.70

Apoptosis: the nexus of liver injury and fibrosis. Hepatology (2004) 2.70

Cytotoxic T cells and viral hepatitis. J Clin Invest (1997) 2.46

Kupffer cell engulfment of apoptotic bodies stimulates death ligand and cytokine expression. Hepatology (2003) 2.45

Regulation of the proinflammatory effects of Fas ligand (CD95L). Science (1998) 2.43

Life and death by death receptors. FASEB J (2009) 2.39

Caspase 8 small interfering RNA prevents acute liver failure in mice. Proc Natl Acad Sci U S A (2003) 2.34

Toxic bile salts induce rodent hepatocyte apoptosis via direct activation of Fas. J Clin Invest (1999) 2.32

Hepatocyte-specific disruption of Bcl-xL leads to continuous hepatocyte apoptosis and liver fibrotic responses. Gastroenterology (2004) 2.18

Hepatocyte death: a clear and present danger. Physiol Rev (2010) 2.18

Transcriptional regulation of Bim by FoxO3A mediates hepatocyte lipoapoptosis. J Biol Chem (2007) 2.01

Free fatty acids sensitise hepatocytes to TRAIL mediated cytotoxicity. Gut (2007) 1.99

Inducible dimerization and inducible cleavage reveal a requirement for both processes in caspase-8 activation. J Biol Chem (2010) 1.99

Fas enhances fibrogenesis in the bile duct ligated mouse: a link between apoptosis and fibrosis. Gastroenterology (2002) 1.98

Portal fibroblasts: Underappreciated mediators of biliary fibrosis. Hepatology (2010) 1.97

Apoptotic body engulfment by a human stellate cell line is profibrogenic. Lab Invest (2003) 1.96

Hepatocyte apoptosis is a pathologic feature of human alcoholic hepatitis. J Hepatol (2001) 1.93

Serum activity of alanine aminotransferase (ALT) as an indicator of health and disease. Hepatology (2008) 1.92

JNK1-dependent PUMA expression contributes to hepatocyte lipoapoptosis. J Biol Chem (2009) 1.82

The alteration of Fas receptor and ligand system in hepatocellular carcinomas: how do hepatoma cells escape from the host immune surveillance in vivo? Hepatology (1999) 1.79

Pan-caspase inhibitor VX-166 reduces fibrosis in an animal model of nonalcoholic steatohepatitis. Hepatology (2009) 1.79

Fatal hepatitis mediated by tumor necrosis factor TNFalpha requires caspase-8 and involves the BH3-only proteins Bid and Bim. Immunity (2009) 1.73

Phagocytosis of apoptotic bodies by hepatic stellate cells induces NADPH oxidase and is associated with liver fibrosis in vivo. Hepatology (2006) 1.71

Bax inhibition protects against free fatty acid-induced lysosomal permeabilization. Am J Physiol Gastrointest Liver Physiol (2006) 1.66

The caspase inhibitor IDN-6556 attenuates hepatic injury and fibrosis in the bile duct ligated mouse. J Pharmacol Exp Ther (2003) 1.60

Apaf-1 and caspase-9 accelerate apoptosis, but do not determine whether factor-deprived or drug-treated cells die. J Cell Biol (2004) 1.57

Differential induction of apoptosis by Fas-Fas ligand interactions in human monocytes and macrophages. J Exp Med (1997) 1.56

Resistance to caspase-independent cell death requires persistence of intact mitochondria. Dev Cell (2010) 1.54

A caspase inhibitor, IDN-6556, ameliorates early hepatic injury in an ex vivo rat model of warm and cold ischemia. Liver Transpl (2007) 1.53

Bile salts mediate hepatocyte apoptosis by increasing cell surface trafficking of Fas. Am J Physiol Gastrointest Liver Physiol (2000) 1.51

Death receptors in liver biology and pathobiology. Hepatology (1999) 1.45

Anti-Fas induces hepatic chemokines and promotes inflammation by an NF-kappa B-independent, caspase-3-dependent pathway. J Biol Chem (2001) 1.44

Hepatic failure and liver cell damage in acute Wilson's disease involve CD95 (APO-1/Fas) mediated apoptosis. Nat Med (1998) 1.42

Histologic predictors of fibrosis progression in liver allografts in patients with hepatitis C virus infection. Clin Gastroenterol Hepatol (2009) 1.41

Oral IDN-6556, an antiapoptotic caspase inhibitor, may lower aminotransferase activity in patients with chronic hepatitis C. Hepatology (2007) 1.38

Death receptor-mediated apoptosis and the liver. J Hepatol (2002) 1.37

Clinical Trial of the Pan-Caspase Inhibitor, IDN-6556, in Human Liver Preservation Injury. Am J Transplant (2007) 1.36

Expression of Fas and Fas-related molecules in human hepatocellular carcinoma. Hum Pathol (2001) 1.27

Expression of P2Y nucleotide receptors and ectonucleotidases in quiescent and activated rat hepatic stellate cells. Am J Physiol Gastrointest Liver Physiol (2004) 1.27

Role of TLR9 in hepatic stellate cells and experimental liver fibrosis. Biochem Biophys Res Commun (2008) 1.23

Cellular FLICE/caspase-8-inhibitory protein as a principal regulator of cell death and survival in human hepatocellular carcinoma. Lab Invest (2003) 1.20

Death receptor-mediated liver injury. Semin Liver Dis (2007) 1.18

Apoptotic body engulfment by hepatic stellate cells promotes their survival by the JAK/STAT and Akt/NF-kappaB-dependent pathways. J Hepatol (2009) 1.17

Significance of Fas antigen-mediated apoptosis in human fulminant hepatic failure. Am J Gastroenterol (2000) 1.14

Apoptosis and liver disease. Am J Med (2000) 1.13

Mcl-1 and Bcl-xL cooperatively maintain integrity of hepatocytes in developing and adult murine liver. Hepatology (2009) 1.12

Increased severity of alcoholic liver injury in female rats: role of oxidative stress, endotoxin, and chemokines. Am J Physiol Gastrointest Liver Physiol (2001) 1.11

Fas-mediated hepatocyte apoptosis is increased by hepatitis C virus infection and alcohol consumption, and may be associated with hepatic fibrosis: mechanisms of liver cell injury in chronic hepatitis C virus infection. J Viral Hepat (2001) 1.10

Cell death and fibrogenesis. Semin Liver Dis (2010) 1.09

Cholestasis increases tumor necrosis factor-related apoptotis-inducing ligand (TRAIL)-R2/DR5 expression and sensitizes the liver to TRAIL-mediated cytotoxicity. J Pharmacol Exp Ther (2002) 1.07

The fractalkine receptor CX3CR1 is involved in liver fibrosis due to chronic hepatitis C infection. J Hepatol (2007) 1.06

Leptin induces phagocytosis of apoptotic bodies by hepatic stellate cells via a Rho guanosine triphosphatase-dependent mechanism. Hepatology (2008) 1.05

Emerging roles of TLR7 and TLR9 in murine SLE. J Autoimmun (2009) 1.03

Inflammation in response to hepatocellular apoptosis. Hepatology (2002) 1.01

Classification, mechanisms of action, and therapeutic applications of inhibitory oligonucleotides for Toll-like receptors (TLR) 7 and 9. Mediators Inflamm (2010) 1.01

CX3CL1/fractalkine shedding by human hepatic stellate cells: contribution to chronic inflammation in the liver. J Cell Mol Med (2009) 1.00

The role of intrahepatic immune effector cells in inflammatory liver injury and viral control during chronic hepatitis B infection. J Viral Hepat (2003) 0.98

The status of Fas and Fas ligand expression can predict recurrence of hepatocellular carcinoma. Br J Cancer (2000) 0.95

Apoptosis mediated by the Fas system in the fulminant hepatitis by hepatitis B virus. J Viral Hepat (2002) 0.93

Apoptosis-related proteins, BCL-2, BAX, FAS, FAS-L and PCNA in liver biopsies of patients with chronic hepatitis B virus infection. Pathol Oncol Res (2000) 0.93

Increased serum soluble Fas in patients with acute liver failure due to paracetamol overdose. Hepatogastroenterology (2003) 0.92

Fas-mediated apoptosis in acute alcoholic hepatitis. Hepatogastroenterology (2003) 0.92

Cell biology: Sent by the scent of death. Nature (2009) 0.91

Detection of the M30 neoepitope as a new tool to quantify liver apoptosis: timing and patterns of positivity on frozen and paraffin-embedded sections. Am J Clin Pathol (2004) 0.91

Apoptotic pathways in primary biliary cirrhosis and autoimmune hepatitis. Liver (2001) 0.88

Apoptosis of biliary epithelial cells in primary biliary cirrhosis and primary sclerosing cholangitis. Liver (2002) 0.86

Fas antigen expression in hepatocellular carcinoma tissues. Oncol Rep (1998) 0.84

Caspase inhibitors for the treatment of hepatitis C. Clin Liver Dis (2009) 0.82

Liver tissue expression of CD80 and CD95 antigens in chronic hepatitis C: relationship with biological and histological disease activities. Microbios (1999) 0.81

Expression of perforin and Fas ligand mRNA in the liver of viral hepatitis. J Clin Immunol (2000) 0.81

Apoptotic cell death takes its toll. Hepatology (2007) 0.80

Apoptosis and the expression of Fas and Fas ligand (FasL) antigen in rejection and reinfection in liver allograft specimens. Transplantation (1999) 0.80

The liver's dance with death: two Bcl-2 guardian proteins from the abyss. Hepatology (2009) 0.80

In situ expression of Granzyme B and Fas-ligand in the liver of viral hepatitis. Liver (2002) 0.79

Articles by these authors

(truncated to the top 100)

Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst (2008) 11.27

Hepatocellular carcinoma: clinical frontiers and perspectives. Gut (2014) 5.79

Hepatocyte apoptosis and fas expression are prominent features of human nonalcoholic steatohepatitis. Gastroenterology (2003) 4.84

Mechanisms of hepatotoxicity. Toxicol Sci (2002) 4.13

Cholangiocarcinoma: advances in pathogenesis, diagnosis, and treatment. Hepatology (2008) 3.95

Diagnosis and management of primary sclerosing cholangitis. Hepatology (2010) 3.60

Free fatty acids induce JNK-dependent hepatocyte lipoapoptosis. J Biol Chem (2006) 3.57

Apoptosis and necrosis in the liver: a tale of two deaths? Hepatology (2006) 3.52

Recommendations for liver transplantation for hepatocellular carcinoma: an international consensus conference report. Lancet Oncol (2011) 3.36

Free fatty acids promote hepatic lipotoxicity by stimulating TNF-alpha expression via a lysosomal pathway. Hepatology (2004) 3.23

Cholangiocarcinoma. Gastroenterology (2005) 3.15

Cellular and molecular mechanisms of liver injury. Gastroenterology (2008) 3.02

Lysosomes in cell death. Oncogene (2004) 3.00

Molecular mechanisms of lipotoxicity in nonalcoholic fatty liver disease. Semin Liver Dis (2008) 2.89

The role of Mcl-1 downregulation in the proapoptotic activity of the multikinase inhibitor BAY 43-9006. Oncogene (2005) 2.89

Pathogenesis, diagnosis, and management of cholangiocarcinoma. Gastroenterology (2013) 2.81

Apoptosis: the nexus of liver injury and fibrosis. Hepatology (2004) 2.70

Impact of multiple transarterial chemoembolization treatments on hepatocellular carcinoma for patients awaiting liver transplantation. Liver Transpl (2015) 2.63

EUS-guided FNA of regional lymph nodes in patients with unresectable hilar cholangiocarcinoma. Gastrointest Endosc (2007) 2.61

Cholangiocarcinomas can originate from hepatocytes in mice. J Clin Invest (2012) 2.56

Clinical diagnosis and staging of cholangiocarcinoma. Nat Rev Gastroenterol Hepatol (2011) 2.51

Kupffer cell engulfment of apoptotic bodies stimulates death ligand and cytokine expression. Hepatology (2003) 2.45

Life and death by death receptors. FASEB J (2009) 2.39

Cholangiocarcinoma. Clin Liver Dis (2008) 2.33

Risk factors for intrahepatic cholangiocarcinoma: association between metformin use and reduced cancer risk. Hepatology (2012) 2.33

Biliary repair and carcinogenesis are mediated by IL-33-dependent cholangiocyte proliferation. J Clin Invest (2014) 2.31

Diet associated hepatic steatosis sensitizes to Fas mediated liver injury in mice. J Hepatol (2003) 2.29

Liver transplantation with neoadjuvant chemoradiation is more effective than resection for hilar cholangiocarcinoma. Ann Surg (2005) 2.23

A comparison of routine cytology and fluorescence in situ hybridization for the detection of malignant bile duct strictures. Am J Gastroenterol (2004) 2.23

MicroRNA-21 is overexpressed in human cholangiocarcinoma and regulates programmed cell death 4 and tissue inhibitor of metalloproteinase 3. Hepatology (2009) 2.23

Cholangiocarcinoma: modern advances in understanding a deadly old disease. J Hepatol (2006) 2.19

Hepatocyte death: a clear and present danger. Physiol Rev (2010) 2.18

Hepatocellular carcinoma: molecular pathways and new therapeutic targets. Semin Liver Dis (2005) 2.18

Interleukin-6 contributes to Mcl-1 up-regulation and TRAIL resistance via an Akt-signaling pathway in cholangiocarcinoma cells. Gastroenterology (2005) 2.03

Induction of intrahepatic cholangiocellular carcinoma by liver-specific disruption of Smad4 and Pten in mice. J Clin Invest (2006) 2.03

Transcriptional regulation of Bim by FoxO3A mediates hepatocyte lipoapoptosis. J Biol Chem (2007) 2.01

Cancer surveillance in patients with primary sclerosing cholangitis. Hepatology (2011) 2.01

Free fatty acids sensitise hepatocytes to TRAIL mediated cytotoxicity. Gut (2007) 1.99

Fas enhances fibrogenesis in the bile duct ligated mouse: a link between apoptosis and fibrosis. Gastroenterology (2002) 1.98

Deleted in breast cancer-1 regulates SIRT1 activity and contributes to high-fat diet-induced liver steatosis in mice. J Clin Invest (2010) 1.97

Apoptotic body engulfment by a human stellate cell line is profibrogenic. Lab Invest (2003) 1.96

Deaths on the liver transplant waiting list: an analysis of competing risks. Hepatology (2006) 1.93

Mcl-1 mediates tumor necrosis factor-related apoptosis-inducing ligand resistance in human cholangiocarcinoma cells. Cancer Res (2004) 1.91

The lysosomal-mitochondrial axis in free fatty acid-induced hepatic lipotoxicity. Hepatology (2008) 1.88

Activated stellate cells express the TRAIL receptor-2/death receptor-5 and undergo TRAIL-mediated apoptosis. Hepatology (2003) 1.86

A pilot study of the safety and tolerability of etanercept in patients with alcoholic hepatitis. Am J Gastroenterol (2004) 1.83

JNK1-dependent PUMA expression contributes to hepatocyte lipoapoptosis. J Biol Chem (2009) 1.82

Enhanced epidermal growth factor receptor activation in human cholangiocarcinoma cells. J Hepatol (2004) 1.80

Interleukin 6 upregulates myeloid cell leukemia-1 expression through a STAT3 pathway in cholangiocarcinoma cells. Hepatology (2005) 1.78

Cathepsin B inactivation attenuates hepatic injury and fibrosis during cholestasis. J Clin Invest (2003) 1.73

Efficacy of neoadjuvant chemoradiation, followed by liver transplantation, for perihilar cholangiocarcinoma at 12 US centers. Gastroenterology (2012) 1.70

Sustained IL-6/STAT-3 signaling in cholangiocarcinoma cells due to SOCS-3 epigenetic silencing. Gastroenterology (2006) 1.68

A prospective comparison of digital image analysis and routine cytology for the identification of malignancy in biliary tract strictures. Clin Gastroenterol Hepatol (2004) 1.66

Bax inhibition protects against free fatty acid-induced lysosomal permeabilization. Am J Physiol Gastrointest Liver Physiol (2006) 1.66

A randomized, double-blinded, placebo-controlled multicenter trial of etanercept in the treatment of alcoholic hepatitis. Gastroenterology (2008) 1.65

Vascular complications after orthotopic liver transplantation after neoadjuvant therapy for hilar cholangiocarcinoma. Liver Transpl (2007) 1.64

Serine 64 phosphorylation enhances the antiapoptotic function of Mcl-1. J Biol Chem (2007) 1.63

Apoptosis in alcoholic and nonalcoholic steatohepatitis. Front Biosci (2005) 1.63

The value of serum CA 19-9 in predicting cholangiocarcinomas in patients with primary sclerosing cholangitis. Dig Dis Sci (2005) 1.63

Advanced cytologic techniques for the detection of malignant pancreatobiliary strictures. Gastroenterology (2006) 1.60

The caspase inhibitor IDN-6556 attenuates hepatic injury and fibrosis in the bile duct ligated mouse. J Pharmacol Exp Ther (2003) 1.60

Pathogenesis of primary sclerosing cholangitis and advances in diagnosis and management. Gastroenterology (2013) 1.58

Liver transplantation for cholangiocarcinoma. Transpl Int (2010) 1.58

Palmitoleate attenuates palmitate-induced Bim and PUMA up-regulation and hepatocyte lipoapoptosis. J Hepatol (2010) 1.56

Apoptosis and cellular activation in the pathogenesis of acute vascular rejection. Circ Res (2002) 1.56

Apotopes and the biliary specificity of primary biliary cirrhosis. Hepatology (2009) 1.55

Classification, diagnosis, and management of cholangiocarcinoma. Clin Gastroenterol Hepatol (2012) 1.55

CHOP and AP-1 cooperatively mediate PUMA expression during lipoapoptosis. Am J Physiol Gastrointest Liver Physiol (2010) 1.54

Trans-peritoneal fine needle aspiration biopsy of hilar cholangiocarcinoma is associated with disease dissemination. HPB (Oxford) (2011) 1.54

Octreotide therapy for advanced hepatocellular carcinoma. J Clin Gastroenterol (2005) 1.53

Biliary apotopes and anti-mitochondrial antibodies activate innate immune responses in primary biliary cirrhosis. Hepatology (2010) 1.53

IL-33 facilitates oncogene-induced cholangiocarcinoma in mice by an interleukin-6-sensitive mechanism. Hepatology (2015) 1.52

"Will all liver transplantation patients eventually die from cancer?". J Hepatol (2005) 1.52

Isocitrate dehydrogenase 1 and 2 mutations in cholangiocarcinoma. Hum Pathol (2012) 1.51

Caveolin-1 can regulate vascular smooth muscle cell fate by switching platelet-derived growth factor signaling from a proliferative to an apoptotic pathway. Arterioscler Thromb Vasc Biol (2003) 1.50

Sorafenib inhibits signal transducer and activator of transcription-3 signaling in cholangiocarcinoma cells by activating the phosphatase shatterproof 2. Hepatology (2009) 1.49

Bile acids activate EGF receptor via a TGF-alpha-dependent mechanism in human cholangiocyte cell lines. Am J Physiol Gastrointest Liver Physiol (2003) 1.48

Tumor necrosis factor-alpha-associated lysosomal permeabilization is cathepsin B dependent. Am J Physiol Gastrointest Liver Physiol (2002) 1.47

The emergence of a new discipline, hepatobiliary oncology. Hepatology (2008) 1.46

TRAIL mediates liver injury by the innate immune system in the bile duct-ligated mouse. Hepatology (2008) 1.45

Tumor necrosis factor-related apoptosis-inducing ligand activates a lysosomal pathway of apoptosis that is regulated by Bcl-2 proteins. J Biol Chem (2007) 1.43

Trail induces cell migration and invasion in apoptosis-resistant cholangiocarcinoma cells. Am J Physiol Gastrointest Liver Physiol (2005) 1.43

Molecular profiling of cholangiocarcinoma shows potential for targeted therapy treatment decisions. Hum Pathol (2013) 1.43

Predictors of disease recurrence following neoadjuvant chemoradiotherapy and liver transplantation for unresectable perihilar cholangiocarcinoma. Transplantation (2006) 1.43

Comparison of methods to detect neoplasia in patients undergoing endoscopic ultrasound-guided fine-needle aspiration. Gastroenterology (2012) 1.43

Proteasome inhibition induces hepatic stellate cell apoptosis. Hepatology (2006) 1.42

Nitric oxide promotes caspase-independent hepatic stellate cell apoptosis through the generation of reactive oxygen species. Hepatology (2008) 1.41

Primary sclerosing cholangitis: summary of a workshop. Hepatology (2006) 1.38

Bile acids inhibit Mcl-1 protein turnover via an epidermal growth factor receptor/Raf-1-dependent mechanism. Cancer Res (2002) 1.37

Inducible nitric oxide synthase up-regulates Notch-1 in mouse cholangiocytes: implications for carcinogenesis. Gastroenterology (2005) 1.37

Death receptor-mediated apoptosis and the liver. J Hepatol (2002) 1.37

Synthetic Smac/DIABLO peptides enhance the effects of chemotherapeutic agents by binding XIAP and cIAP1 in situ. J Biol Chem (2002) 1.36

Mechanisms of lipotoxicity in NAFLD and clinical implications. J Pediatr Gastroenterol Nutr (2011) 1.35

Liver transplantation for unresectable perihilar cholangiocarcinoma. Semin Liver Dis (2004) 1.34

Mechanisms of liver injury: an overview. Curr Mol Med (2003) 1.34

Hypoxia stimulates proliferation of human hepatoma cells through the induction of hexokinase II expression. J Hepatol (2005) 1.32

Bile acids up-regulate death receptor 5/TRAIL-receptor 2 expression via a c-Jun N-terminal kinase-dependent pathway involving Sp1. J Biol Chem (2003) 1.32

Bile acids induce cyclooxygenase-2 expression via the epidermal growth factor receptor in a human cholangiocarcinoma cell line. Gastroenterology (2002) 1.31

Mortality and hospital utilization for hepatocellular carcinoma in the United States. Gastroenterology (2005) 1.27

The anti-apoptotic protein Mcl-1 inhibits mitochondrial Ca2+ signals. J Biol Chem (2005) 1.24